Lund-based gene therapy company CombiGene continues to advance its main project CG01 ahead of the phase I studies scheduled to begin next year. The company is now ready for GMP production of drug substance and has also begun a collaboration with UK-based Neurochase in order to optimise the administration of the candidate.
